Copper and iron disorders of the brain

Annual Review of Neuroscience

Volumn 30, Issue , 2007, Pages 317-337

  Madsen, Erik ^a   Gitlin, Jonathan D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Astrocyte; Blood brain barrier; Ferroxidase; Golgi; Neurodegeneration; p type Atpase

Indexed keywords

COPPER; IRON;

BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COPPER DEFICIENCY; COPPER METABOLISM; GENETIC DISORDER; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; METABOLIC DISORDER; MOLECULAR GENETICS; NEUROBIOLOGY; NEUROCHEMISTRY; PRIORITY JOURNAL; RARE DISEASE; REVIEW;

ANIMALS; BRAIN; BRAIN DISEASES, METABOLIC; COPPER; FRIEDREICH ATAXIA; GENETIC PREDISPOSITION TO DISEASE; HEPATOLENTICULAR DEGENERATION; HOMEOSTASIS; HUMANS; IRON; IRON METABOLISM DISORDERS; MENKES KINKY HAIR SYNDROME;

EID: 34547782810     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.30.051606.094232     Document Type: Review

References (135)

1. Ajioka RS, Phillips JD, Kushner JP. 2006. Biosynthesis of heme in mammals. Biochim. Biophys. Acta 1763:723-36
2. Andrews NC. 2002. A genetic view of iron homeostasis. Semin Hematol. 39:227-34
3. Andrews NC, Schmidt PJ. 2007. Iron homeostasis. Annu. Rev. Physiol. 69:69-85
4. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, et al. 1997. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276:1709-12
5. Balamurugan K, Schaffner W. 2006. Copper homeostasis in eukaryotes: teetering on a tightrope. Biochim.. Biophys. Acta 1763:737-46
6. Barnard RO, Best PV, Erdohazi M. 1978. Neuropathology of Menkes' disease. Dev. Med. Child Neurol. 20:586-97
7. Bradbury MW. 1997. Transport of iron in the blood-brain-cerebrospinal fluid system. J. Neurochem. 69:443-54
8. Brown DR, Qin K, Herms JW, Madlung A, Manson J, et al. 1997. The cellular prion protein binds copper in vivo. Nature 390:684-87
9. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. 1993. The Wilson disease gene is a putative copper transporting P-type Atpase similar to the Menkes gene. Nat. Genet. 5:327-37
10. Bush AI. 2000. Metals and neuroscience. Cum. Opin. Chem. Biol. 4:184-91
11. Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE, et al. 2006. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase dexrasl. Neuron 51:431-40
12. Chelly J, Turner Z, Tonnesen T, Petterson A, Ishikawa-Brush Y, et al. 1993. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat. Genet. 3:14-19
13. Chinnery PF, Crompton DE, Birchall D, Jackson MJ, Coulthard A, et al. 2007. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130:110-19
14. Christodoulou J, Danks DM, Sarkar B, Baerlocher KE, Casey R, et al. 1998. Early treatment of Menkes disease with parenteral copper-histidine: long-term follow-up of four treated patients. Am. J. Med. Genet. 76:154-64
15. Craven CM, Alexander J, Eldridge M, Kushner JP, Bernstein S, Kaplan J. 1987. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc. Natl. Acad. Sci. USA 84:3457-61
16. Culotta VC, Gitlin JD. 2001. Disorders of copper transport. In The Molecular and Metabolic Basis of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, pp. 3105-36. New York: McGraw-Hill
17. Culotta VC, Yang M, O'Halloran TV. 2006. Activation of superoxide dismutases: putting the metal to the pedal. Biochim. Biophys. Acta 1763:747-58
18. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, et al. 2001. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28:350-54
19. Czyzyk TA, Ning Y, Hsu MS, Peng B, Mains RE, et al. 2005. Deletion of peptide amidation enzymatic activity leads to edema and embryonic lethality in the mouse. Dev. Biol. 287:301-13
20. De Domenico I, Ward DM, Musci G, Kaplan J. 2006. Iron overload due to mutations in ferroportin. Haematologica 91:92-95
21. Dening TR. 1991. The neuropsychiatry of Wilson's disease: a review. Int. J. Psychiatr. Med. 21:135-48
22. Doraiswamy PM, Fineffock AE. 2004. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol. 3:431-34
23. Doreulee N, Yanovsky Y, Haas HL. 1997. Suppression of long-term potentiation in hippocampal slices by copper. Hippocampus 7:666-69
24. Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, et al. 1996. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335:1169-75
25. El Meskini R, Cline LB, Eipper BA, Ronnett GV. 2005. The developmentally regulated expression of Menkes protein Atp7A suggests a role in axon extension and synaptogenesis. Dev. Neurosci. 27:333-48
26. Emre S, Atillasoy EO, Ozdemir S, Schilsky M, Rathna Vanna CV, et al. 2001. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation 72:1232-36
27. Ferenci P. 2004. Pathophysiology and clinical features of Wilson disease. Metab. Brain Dis. 19:229-39
28. Gaeta A, Hider RC. 2005. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146:1041-59
29. Geller TJ, Pan Y, Martin DS. 1997. Early neuroradiologic evidence of degeneration in Menkes' disease. Pediatr. Neurol. 17:255-58
30. Gitlin JD. 1998. Aceruloplasminemia. Pediatr. Res. 44:271-76
31. Gitlin JD. 2003. Wilson disease. Gastroenterology 125:1868-77
32. Gollan JL, Deller DJ. 1973. Studies on the nature and excretion of biliary copper in man. Clin. Sci. 44:9-15
33. Gollan JL, Gollan TJ. 1998. Wilson disease in 1998: genetic, diagnostic and therapeutic aspects. J. Hepatol. 28(Suppl. 1):28-36
34. Gregory A, Hayflick SJ. 2005. Neurodegeneration with brain iron accumulation. Folia Neuropathol. 43:286-96
35. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, et al. 2005. Imaging iron stores in the brain using magnetic resonance imaging. Magn. Reson. Imaging 23:1-25
36. Hamza I, Faisst A, Prohaska J, Chen J, Gruss P, Gitlin JD. 2001. The metallochaperone Atox1 plays a critical role in perinatal copper homeostasis. Proc. Natl. Acad. Sci. USA 98:6848-52
37. Hamza I, Gitlin JD. 2002. Copper chaperones for cytochrome c oxidase and human disease. J. Bioenerg. Biomembr. 34:381-88
38. Hamza I, Prohaska J, Gitlin JD. 2003. Essential role for Atox1 in the copper-mediated intracellular trafficking of the Menkes Atpase. Proc. Natl. Acad. Sci. USA 100:1215-20
39. Hardingham GE, Bading H. 2003. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 26:81-89
40. Harris ZL, Durley AP, Man TK, Gidin JD. 1999. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci. USA 96:10812-17
41. Harris ZL, Klonip LW, Gidin JD. 1998. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am. J. Clin. Nutr. 67:972S-77
42. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. 1995. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. USA 92:2539-43
43. Hartter DE, Barnea A. 1988. Evidence for release of copper in the brain: depolarization-induced release of newly taken-up 67copper. Synapse 2:412-15
44. Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, et al. 2003. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N. Engl. J. Med. 348:33-40
45. Hellman NE, Gitlin JD. 2002. Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 22:439-58
46. Hentze MW, Muckenthaler MU, Andrews NC. 2004. Balancing acts: molecular control of mammalian iron metabolism. Cell 117:285-97
47. Ho YS, Gargano M, Cao J, Bronson RT, Heimler I, Hutz RJ. 1998. Reduced fertility in female mice lacking copper-zinc superoxide dismutase. J. Biol. Chem. 273:7765-69
48. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. 2003. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J. Biol. Chem. 278:14387-93
49. Jeong SY, David S. 2003. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278:27144-48
50. Jeong SY, David S. 2006. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J. Neurosci. 26:9810-19
51. Johnson MA, Kuo YM, Westaway SK, Parker SM, Ching KH, et al. 2004. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann. N.Y. Acad. Sci. 1012:282-98
52. Kaler SG. 1998. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr. Dev. Pathol. 1:85-98
53. Kaler SG, Buist NR, Holmes CS, Goldstein DS, Miller RC, Gahl WA. 1995. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann. Neurol. 38:921-28
54. Kaneko K, Yoshida K, Arima K, Ohara S, Miyajima H, et al. 2002. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J. Neuropathol. Exp. Neurol. 61:1069-77
55. Kardos J, Kovacs I, Hajos F, Kalman M, Simonyi M. 1989. Nerve endings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability. Neurosci. Lett. 103:139-44
56. Keen CL, Uriu-Hare JY, Hawk SN, Jankowski MA, Daston GP, et al. 1998. Effect of copper deficiency on prenatal development and pregnancy outcome. Am.. J. Clin. Nutr. 67:1003S-11
57. Kelly EJ, Palmiter RD. 1996. Amurine model of Menkes disease reveals a physiological function of metallothionein. Nat. Genet. 13:219-22
58. Klomp LW, Farhangrazi ZS, Dugan LL, Gitlin JD. 1996. Ceruloplasmin gene expression in the murine central nervous system. J. Clin. Invest. 98:207-15
59. Klomp LW, Gidin JD. 1996. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum. Mol. Genet. 5:1989-96
60. Kodama H, Murata Y, Kobayashi M. 1999. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr. Int. 41:423-29
61. Kono S, Miyajima H. 2006. Molecular and pathological basis of aceruloplasminemia. Biol. Res. 39:15-23
62. Koury MJ, Ponka P. 2004. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu. Rev. Nutr. 24:105-31
63. Kozma M, Szerdahelyi P, Kasa P. 1981. Histochemical detection of zinc and copper in various neurons of the central nervous system. Acta Histochem. 69:12-17
64. Kumar N, Gross JBJ, Ahlskog JE. 2004. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 63:33-39
65. Kuo YM, Gybina AA, Pyatskowit JW, Gitschier J, Prohaska JR. 2 006. Copper transport protein (Ctrl) levels in mice are tissue specific and dependent on copper status. J. Nutr. 136:21-26
66. Kuo YM, Zhou B, Cosco D, Gitschier J. 2001. The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc. Natl. Acad. Sci. USA 98:6836-41
67. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, et al. 2001. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27:209-14
68. Leary SC, Cobine PA, Kaufman BA, Guercin GH, Mattman A, et al. 2007. The human cytochrome c oxidase assembly factors SCO1 and SCO2 have regulatory roles in the maintenance of cellular copper homeostasis. Cell Metab. 5:9-20
69. Lee DW, Andersen JK, Kaur D. 2006. Iron dysregulation and neurodegeneration: the molecular connection. Mol. Interv. 6:89-97
70. Lee J, Prohaska JR, Thiele DJ. 2001. Essential role for mammalian copper transporter Ctrl in copper homeostasis and embryonic development. Proc. Natl. Acad. Sci. USA 98:6842-47
71. Leventer RJ, Kornberg AJ, Phelan EM, Kean MJ. 1997. Early magnetic resonance imaging findings in Menkes' disease. J. Child Neurol. 12:222-24
72. Levi S, Cozzi A, Arosio P. 2005. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best. Pract. Res. Clin. Haematol. 18:265-76
73. Lill R, Mühlenhoff U. 2006. Iron-sulfur protein biogenesis in eukaryotes: components and mechanisms. Annu. Rev. Cell Dev. Biol. 22:457-86
74. Logan JI, Harveyson KB, Wisdom GB, Hughes AE, Archbold GP. 1994. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. Q. J. Med. 87:663-70
75. Lozoff B, Beard J, Connor J, Barbara F, Georgieff M, Schallert T. 2006. Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr. Rev. 64:S34-43; discussion S72-91
76. Lu W, Man H, Ju W, Trimble WS, MacDonald JF, Wang YT. 2001. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 29:243-54
77. Lutsenko S, Petris MJ. 2003. Function and regulation of the mammalian copper-transporting Atpases: insights from biochemical and cell biological approaches. J. Membr. Biol. 191:1-12
78. Maciel P, Cruz VT, Constante M, Iniesta I, Costa MC, et al. 2005. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 65:603-5
79. Mancuso M, Davidzon G, Kurlan RM, Tawil R, Bonilla E, et al. 2005. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J. Neuropathol. Exp. Neurol. 64:280-94
80. Mendelsohn BA, Yin C, Johnson SL, Wilm TP, Solnica-Krezel L, Gitlin JD. 2006. Atp7a determines a hierarchy of copper metabolism essential for notochord development. Cell Metab. 4:155-62
81. Mercer JF. 1998. Menkes syndrome and animal models. Am. J. Clin. Nutr. 67:1022S-28
82. Mercer JF, Livingston J, Hall B, Paynter JA, Begy C, et al. 1993. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat. Genet. 3:20-25
83. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. 1987. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 37:761-67
84. Moller LB, Tumer Z, Lund C, Petersen C, Cole T, et al. 2000. Similar splice-site mutations of the Atp7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. Am. J. Hum. Genet. 66:1211-20
85. Moos T, Morgan EH. 2004. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann. N.Y.Acad. Sci. 1012:14-26
86. Moos T, Skjoerringe T, Gosk S, Morgan EH. 2006. Brain capillary endothelial cells mediate iron transport into the brain by segregating iron from transferrin without the involvement of divalent metal transporter 1. J. Neurochem. 98:1946-58
87. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, et al. 2006. PLA2G6, encoding a phospholipase A(2), is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 38:752-54
88. Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, et al. 1995. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann. Neurol. 37:646-56
89. Nemeth E, Ganz T. 2006. Regulation of iron metabolism by hepcidin. Annu. Rev. Nutr. 26:323-42
90. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090-93
91. Nittis T, Gidin JD. 2002. The copper-iron connection: hereditary aceruloplasminemia. Semin. Hematol. 39:282-89
92. Nose Y, Kim BE, Thiele DJ. 2006. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab. 4:235-44
93. O'Halloran TV, Culotta VC. 2000. Metallochaperones, an intracellular shuttle service for metal ions. J. Biol. Chem. 275:25057-60
94. Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L. 1991. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J. Neurol. 238:281-87
95. Oide T, Yoshida K, Kaneko K, Ohta M, Arima K. 2006. Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropathol. Appl. Neurobiol. 32:170-76
96. Okeda R, Gei S, Chen I, Okaniwa M, Shinomiya M, Matsubara O. 1991. Menkes' kinky hair disease: morphological and immunohistochemical comparison of two autopsied patients. Acta Neuropathol. (Berl.) 81:450-57
97. Patel BN, Dunn RJ, David S. 2000. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J. Biol. Chem.. 275:4305-10
98. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. 2002. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J. Neurosci. 22:6578-86
99. Pena MM, Lee J, Thiele DJ. 1999. A delicate balance: homeostatic control of copper uptake and distribution. J. Nutr. 129:1251-60
100. Petris MJ, Mercer JF, Culvenor JG, Lockhart P, Gleeson PA, Camakaris J. 1996. Ligand-regulated transport of the Menkes copper P-type Atpase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. EMBO J. 15:6084-95
101. Pietrangelo A. 2006a. Hereditary hemochromatosis. Annu. Rev. Nutr. 26:251-70
102. Pietrangelo A. 2006b. Hereditary hemochromatosis. Biochim. Biophys. Acta 1763:700-10
103. Ponka P. 1999. Cellular iron metabolism. Kidney Int. 69(Suppl.):S2-11
104. Ponka P. 2004. Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann. N.Y. Acad. Sci. 1012:267-81
105. Prodan CI, Bottomley SS, Holland NR, Lind SE. 2006. Relapsing hypocupraemic myelopathy requiring high-dose oral copper replacement. J. Neurol. Neuros. Psychiatr. 77:1092-93
106. Prohaska JR, Brokate B. 2002. The timing of perinatal copper deficiency in mice influences offspring survival. J. Nutr. 132:3142-45
107. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, et al. 2001. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27:181-86
108. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV. 1999. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284:805-8
109. Rouault TA. 2006. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2:406-14
110. Rouault TA, Tong WH. 2005. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat. Rev. Mol. Cell. Biol. 6:345-51
111. Sato M, Ohtomo K, Daimon T, Sugiyama T, Iijima K. 1994. Localization of copper to afferent terminals in rat locus ceruleus, in contrast to mitochondrial copper in cerebellum. J. Histochem. Cytochem. 42:1585-91
112. Schaefer M, Gidin JD. 1999. Genetic disorders of membrane transport. IV Wilson's disease and Menkes disease. Am. J. Physiol. 276:G311-14
113. Schlief M, West T, Craig A, Holtzman D, Gitlin J. 2006. Role of the Menkes copper transporting Atpase in NMDA receptor-mediated neuronal toxicity. Proc. Natl. Acad. Sci. USA 103:14919-24
114. Schlief ML, Craig AM, Gidin JD. 2005. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J. Neurosci. 25:239-46
115. Schlief ML, Gitlin JD. 2006. Copper homeostasis in the CNS: a novel link between the NMDA receptor and copper homeostasis in the hippocampus. Mol. Neurobiol. 33:81-90
116. Schumacher G, Platz KP, Mueller AR, Neuhaus R, Luck W, et al. 2001. Liver transplantation in neurologic Wilson's disease. Transplant. Proc. 33:1518-19
117. Shaw GC, Cope JJ, Li L, Corson K, Hersey C, et al. 2006. Mitoferrin is essential for erythroid iron assimilation. Nature 440:96-100
118. Sparks DL, Schreurs BG. 2003. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 100:11065-69
119. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, et al. 1993. The Wilson disease gene is a copper transporting Atpase with homology to the Menkes disease gene. Nat. Genet. 5:344-50
120. Tao TY, Gitlin JD. 2003. Hepatic copper metabolism: insights from genetic disease. Hepatology 37:1241-47
121. Thomas M, Jankovic J. 2004. Neurodegenerative disease and iron storage in the brain. Curr. Opin. Neurol. 17:437-42
122. Trombley PQ, Shepherd GM. 1996. Differential modulation by zinc and copper of amino acid receptors from rat olfactory bulb neurons. J. Neurophysiol. 76:2536-46
123. Vidal R, Ghetti B, Takao M, Brefel-Courbon C, Uro-Coste E, et al. 2004. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J. Neuropathol. Exp. Neurol. 63:363-80
124. Vlachova V, Zemkova H, Vyklicky LJ. 1996. Copper modulation of NMDA responses in mouse and rat cultured hippocampal neurons. Eur. J. Neurosci. 8:2257-64
125. Voncken M, Ioannou P, Delatycki MB. 2004. Friedreich ataxia-update on pathogenesis and possible therapies. Neurogenetics 5:1-8
126. Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. 1993. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting Atpase. Nat. Genet. 3:7-13
127. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, et al. 1999. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. 21:195-99
128. Waggoner DJ, Bartnikas TB, Gitlin JD. 1999. The role of copper in neurodegenerative disease. Neurobiol. Dis. 6:221-30
129. Weiser T, Wienrich M. 1996. The effects of copper ions on glutamate receptors in cultured rat cortical neurons. Brain Res. 742:211-18
130. Wong PC, Waggoner D, Subramaniam JR, Tessarollo L, Bartnikas TB, et al. 2000. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc. Natl. Acad. Sci. USA 97:2886-91
131. Wu LJ, Leenders AG, Cooperman S, Meyron-Holtz E, Smith S, et al. 2004. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res. 1001:108-17
132. Yamaguchi Y, Heiny ME, Gitlin JD. 1993. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem. Biophys. Res. Commun. 197:271-77
133. Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, et al. 1995. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat. Genet. 9:267-72
134. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. 2004. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5:863-73
135. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. 2001. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet. 28:345-49